{
    "organizations": [],
    "uuid": "719fb2b87561ac1aee6dc1faaa75b71075fc7f6a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mithra-announces-very-promising-he/brief-mithra-announces-very-promising-hemostasis-results-for-estelle-idUSFWN1PY0EK",
    "ord_in_thread": 0,
    "title": "BRIEF-Mithra Announces Very Promising Hemostasis Results For Estelle​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - MITHRA PHARMACEUTICALS SA:\n* ‍MITHRA PHARMACEUTICALS SA - MITHRA ANNOUNCES VERY PROMISING HEMOSTASIS RESULTS FOR ESTELLE®​\n* ‍RESULTS POINT TO MINIMAL CHANGES IN MARKERS OF COAGULATION AND FIBRINOLYSIS​\n* ‍DETAILED RESULTS AVAILABLE IN COMING WEEKS * ‍RESULTS PRESENTATIONS AT SCIENTIFIC CONFERENCES PLANNED IN Q1/Q2​\n* ‍OBTAINED PROMISING RESULTS FOR ITS PHASE II HEMOSTASIS STUDY OF ESTELLE​ Source text : bit.ly/2EPQxp7 Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-08T14:41:00.000+02:00",
    "crawled": "2018-02-09T16:37:48.055+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "mithra",
        "pharmaceutical",
        "sa",
        "pharmaceutical",
        "sa",
        "mithra",
        "announces",
        "promising",
        "hemostasis",
        "result",
        "point",
        "minimal",
        "change",
        "marker",
        "coagulation",
        "result",
        "available",
        "coming",
        "week",
        "presentation",
        "scientific",
        "conference",
        "planned",
        "promising",
        "result",
        "phase",
        "ii",
        "hemostasis",
        "study",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}